Table 3.

Uterine Fibroid Symptom and Quality of Life Questionnaire Changes for All Women Categorized as Nonresponders

	Placebo	Elagolix+add-back therapy
Symptom severity
Baseline  Mean ± SE	n = 150 60.4 ± 1.7	n = 66 58.8 ± 2.6
3 months  Change from baseline p	n = 146 −16.3 ± 1.7	n = 60 −24.4 ± 2.7 0.01**
6 months  Change from baseline  p	n = 135 −8.9 ± 1.7	n = 39 −11.2 ± 3.2 0.52
Final month  Change from baseline  p	n = 150 −8.3 ± 1.7	n = 66 −13.5 ± 2.6 0.09
HRQoL Total
Baseline  Mean ± SE	n = 149 43.1 ± 1.8	n = 66 46.6 ± 2.8
3 months  Change from baseline  p	n = 145 13.2 ± 1.8	n = 60 25.5 ± 2.9 <0.001***
6 months Change from baseline p	n = 134 8.6 ± 1.9	n = 39 16.2 ± 3.5 0.054
Final month Change from baseline p	n = 149 8.4 ± 1.8	n = 66 15.9 ± 2.8 0.025*

Unless otherwise noted, values are LS mean ± standard error obtained from an analysis of covariance model with treatment and study as the main effects and baseline as a covariate. Symptom Severity scores range from 0 to 100 with higher scores indicating increased severity. HRQoL scores range from 0 to 100 with higher scores indicating better quality of life.

HRQoL, health-related quality of life; SE, standard error.